EGM
MLTX icon

Engineers Gate Manager’s MoonLake Immunotherapeutics MLTX Stock Holding History

Engineers Gate Manager’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.17M Buy
+111,590
New +$2.02M 0.03% 646
2025
Q4 		– Sell
-58,810
Closed -$422K – 2371
2025
Q3 		$422K Buy
+58,810
New +$3.07M ﹤0.01% 1587
2024
Q3 		– Sell
-12,269
Closed -$539K – 2290
2024
Q2 		$539K Buy
+12,269
New +$520K 0.01% 1186

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Engineers Gate Manager's MLTX Position: Q2 2026 in Review

Engineers Gate Manager opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 111,590 shares worth $2.17M. The stake represents 0.03% of the portfolio and ranks #646 among its holdings. This is a return to the name: Engineers Gate Manager previously reported a position in MLTX as recently as Q3 2025.

Engineers Gate Manager first reported a position in MLTX in Q2 2024 and has held it in 3 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Engineers Gate Manager held 111,590 shares of MoonLake Immunotherapeutics worth $2.17M as of Q2 2026.
  • MoonLake Immunotherapeutics was a new Engineers Gate Manager position in Q2 2026.
  • MoonLake Immunotherapeutics made up 0.03% of Engineers Gate Manager's portfolio in Q2 2026, its #646 holding.
  • Engineers Gate Manager first reported a position in MoonLake Immunotherapeutics in Q2 2024 and has held it in 3 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.